We're possibly getting closer to saving thousands of newborns from a potentially nasty illness, and death. Novavax, a clinical-stage biotechnology company, states that it's reached a milestone in a clinical trial for the highly-anticipated vaccine for respiratory syncytial virus, or RSV.
